RANBAXY
GenericsRANBAXY is a generic drug manufacturer focused on Infectious Disease, Immunology, Gastroenterology.
RANBAXY's Key Drugs
RANBAXY's core commercial portfolio centers on RIVASTIGMINE, spanning Infectious Disease and Immunology — its most strategically important drugs approved in the last 15 years.
RANBAXY's Recent FDA Approvals
New NDA/BLA approvals for RANBAXY over the last two years — novel drugs only, excluding generics and label supplements.
RANBAXY's Therapeutic Areas
RANBAXY's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Immunology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
RANBAXY's Top Competitors
RANBAXY's closest competitors by therapeutic-area and drug-target overlap include Pfizer, APOTHECON, and PHARMACIA AND UPJOHN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
RANBAXY Pipeline Snapshot
Active clinical trials for RANBAXY across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • RIVASTIGMINE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1964-11-06
- Latest
- 2018-11-06
- Applications
- 53